These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21696825)

  • 1. CASP8AP2 is a promising prognostic indicator in pediatric acute lymphoblastic leukemia.
    Jiao Y; Cui L; Gao C; Li W; Zhao X; Liu S; Wu M; Deng G; Li Z
    Leuk Res; 2012 Jan; 36(1):67-71. PubMed ID: 21696825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
    Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
    Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expression of
    Cui L; Gao C; Wang CJ; Liu SG; Wu MY; Zhang RD; Li ZG
    Pediatr Hematol Oncol; 2020 Nov; 37(8):732-746. PubMed ID: 32804017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
    Flotho C; Coustan-Smith E; Pei D; Iwamoto S; Song G; Cheng C; Pui CH; Downing JR; Campana D
    Blood; 2006 Aug; 108(3):1050-7. PubMed ID: 16627760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia.
    Yang YL; Lin SR; Chen JS; Lin SW; Yu SL; Chen HY; Yen CT; Lin CY; Lin JF; Lin KH; Jou ST; Hu CY; Chang SK; Lu MY; Chang HH; Chang WH; Lin KS; Lin DT
    Leuk Res; 2010 Jan; 34(1):18-23. PubMed ID: 20109966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia.
    Juárez-Velázquez R; Reyes-León A; Salas-Labadía C; Rivera-Luna R; Velasco-Hidalgo L; López-Hernández G; López-Santiago N; Paredes-Aguilera R; Domínguez-López A; Bernáldez R; Pérez-Vera P
    Leuk Lymphoma; 2014 Oct; 55(10):2305-11. PubMed ID: 24397596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of two CpG sites upstream of CASP8AP2 promoter influences gene expression and treatment outcome in childhood acute lymphoblastic leukemia.
    Li ZG; Jiao Y; Li WJ; Deng GR; Cui L; Gao C; Zhao XX; Wu MY; Jia HT
    Leuk Res; 2013 Oct; 37(10):1287-93. PubMed ID: 23953914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
    Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
    Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
    J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia.
    Levett D; Middleton P; Cole M; Reid MM
    Med Pediatr Oncol; 2001 Mar; 36(3):365-71. PubMed ID: 11241438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.